Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Advertisement
Set Alert for Articles By Jung Won Shin

Latest From Jung Won Shin

ImmuneOncia: A PD-L1 Latecomer Hoping To Break Into The Market

Emerging Company Profile: ImmuneOncia may be late entering the market for PD-L1 inhibitors, but the joint venture between Yuhan and Sorrento Therapeutics aims to develop best-in-class immuno-oncology drugs with differentiated products and strategy.

StartUps and SMEs Companies

What's Behind The Success Of Korean Biosimilars?

Celltrion and Samsung Bioepis are moving fast to grab leading positions in the global biosimilars space, but how have these two firms got to where there are now? Scrip takes a look at what is driving their success and where they are heading next.

South Korea Biosimilars

Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals

Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.

Deals M & A

M&A Buzz In Korea: CJ HealthCare On the Block

CJ Group plans to sell its healthcare affiliate, in what could potentially emerge as the first major M&A deal involving a South Korean pharma firm in recent years. Although the company has not ruled out the option of an initial public offering as an alternative, the sale plan possibly reflects the changing dynamics in the Korean pharma industry.

Commercial Deals

Dong-A Mulls Fresh Options After Allergan Ends Evogliptin Deal

With Allergan handing back the global development and sales rights of evogliptin as a NASH therapy to Dong-A, the South Korean firm is now considering an alternative business model around the DPP-4 inhibitor.

Commercial Deals

Mixed Results From ReGenTree's DES Therapy In Second Phase III

ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.

Research & Development Clinical Trials
See All
Advertisement
UsernamePublicRestriction

Register